New combo therapy shows promise for HER2-low breast cancer patients
NCT ID NCT04556773
First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 26 times
Summary
This study tests a drug called trastuzumab deruxtecan (T-DXd) combined with other cancer medicines in people whose breast cancer has spread and has low levels of a protein called HER2. The main goals are to see if the combinations are safe and to find the best doses. About 138 adults with this type of breast cancer will take part. The study is not yet complete, but it may lead to better treatment options for patients who currently have limited choices.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Commack, New York, 11725, United States
-
Research Site
Harrison, New York, 10604, United States
-
Research Site
New York, New York, 10029, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
Uniondale, New York, 11553, United States
-
Research Site
Chapel Hill, North Carolina, 27514, United States
-
Research Site
Chattanooga, Tennessee, 37404, United States
-
Research Site
Germantown, Tennessee, 38138, United States
-
Research Site
Fort Worth, Texas, 76104, United States
-
Research Site
East Melbourne, 3002, Australia
-
Research Site
Westmead, 2145, Australia
-
Research Site
Edegem, 2650, Belgium
-
Research Site
Leuven, 3000, Belgium
-
Research Site
Ottignies, 1340, Belgium
-
Research Site
Goiânia, 74605-070, Brazil
-
Research Site
Porto Alegre, 90035-003, Brazil
-
Research Site
Porto Alegre, 90110-270, Brazil
-
Research Site
São Paulo, 03102-002, Brazil
-
Research Site
São Paulo, 04543-000, Brazil
-
Research Site
Kelowna, British Columbia, V1Y 5L3, Canada
-
Research Site
Québec, Quebec, G1J 1Z4, Canada
-
Research Site
Villejuif, 94805, France
-
Research Site
Monterrey, 64710, Mexico
-
Research Site
Moscow, 115478, Russia
-
Research Site
Moscow, 143442, Russia
-
Research Site
Saint Petersburg, 199226, Russia
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Kaohsiung City, 82445, Taiwan
-
Research Site
Taichung, 40443, Taiwan
-
Research Site
Taipei, 100, Taiwan
-
Research Site
Taipei, 11217, Taiwan
-
Research Site
Taipei, 114, Taiwan
-
Research Site
Taipei, 235, Taiwan
-
Research Site
Taoyuan, 333, Taiwan
Conditions
Explore the condition pages connected to this study.